Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, AstraZeneca Pharma India has informed that based on the recommendation of the Nomination and Remuneration Committee, the Board of Directors of the Company has approved the appointment of Praveen Akkinepally as the Business Unit Head – Oncology with effect from November 1, 2023. Praveen will be part of the Senior Management team of the Company. In this regard, the company has enclosed the details as required under the SEBI Circular SEBI/HO/CFD/CFDPoD-1/P/CIR/2023/123 dated July 13, 2023 as Annexure – A.
The above information is a part of company’s filings submitted to BSE.
